Molecular detection of human telomerase mRNA (hTERT-mRNA) in Egyptian patients with hepatocellular carcinoma

Hepatitis Monthly

Volumn 9, Issue 2, 2009, Pages 114-121

  El Saeed, Gehan Kamal ^a   El Bassuoni, Maha A ^a   El Saeed, Hala Hany ^b   Gaweesh, Iman A ^a   Soliman, Mohamed A ^a   Attiya, Hatim ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Chronic Liver Disease; Hepatocellular Carcinoma; Telomerase

Indexed keywords

ALPHA FETOPROTEIN; MESSENGER RNA; TELOMERASE;

ARTICLE; BLOOD CELL COUNT; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE MARKER; ECHOGRAPHY; ENZYME ACTIVE SITE; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 70349289689     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bae JS, Park SJ, Park KB, et al. Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alphafetoprotein but no occurrence of hepatocellular carcinoma. Korean J Intern Med. 2005;20(1):80-5.
2. Iliopoulos D, Satra M, Drakaki A, Poultsides GA, Tsezou A. Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. Int J Oncol. 2009;34(2):391-9.
3. Arrieta O, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernandez-Pedro N. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer. 2007;7:28.
4. Bertuch AA, Lundblad V. The maintenance and masking of chromosome termini. Curr Opin Cell Biol. 2006;18(3):247-53.
5. Bryce LA, Morrison N, Hoare SF, Muir S, Keith WN. Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization. Neoplasia. 2000; 2(3): 197-201.
6. Davis GL, Dempster J, Meler JD, et al. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21(3):266-80.
7. Ancelin K, Brunori M, Bauwens S, et al. Targeting assay to study the cis functions of human telomeric proteins: evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2. Mol Cell Biol. 2002;22(10):3474-87.
8. Song J, Kim C, Ochoa ER. Sleeping Beauty-mediated suicide gene therapy of hepatocellular carcinoma. Biosci Biotechnol Biochem. 2009; 73(1):165-8.
9. Perez JM, Grimm J, Josephson L, Weissleder R. Integrated nanosensors to determine levels and functional activity of human telomerase. Neoplasia. 2008;10(10):1066-72.
10. Wu W, Yao DF, Qiu LW, et al. Abnormal expression of hepatomas and circulating telomerase and its clinical values. Hepatobiliary Pancreat Dis Int. 2005;4(4):544-9.
11. Nagao K, Tomimatsu M, Endo H, Hisatomi H, Hikiji K. Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol. 1999;34(1):83-7.
12. Tatsuma T, Goto S, Kitano S, Lin YC, Lee CM, Chen CL. Telomerase activity in peripheral blood for diagnosis of hepatoma. J Gastroenterol Hepatol. 2000;15(9):1064-70.
13. Miura N, Shiota G, Nakagawa T, et al. Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patients with hepatocellular carcinoma. Oncology. 2003;64(4):430-4.
14. Miura N, Maeda Y, Kanbe T, et al. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res. 2005;11(9):3205-9.
15. Yao DF, Wu W, Yao M, et al. Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma. World J Gastroenterol. 2006; 12(31):4966-72.
16. Satra M, Gatselis N, Iliopoulos D, Zacharoulis D, Dalekos GN, Tsezou A. Real-time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis. J Viral Hepat. 2007;14(1):41-7.
17. Miura N, Maruyama S, Oyama K, et al. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology. 2007;72 Suppl 1:45-51.
18. Cortez-Gonzalez X, Zanetti M. Telomerase immunity from bench to bedside: round one. J Transl Med. 2007;5:12.
19. Fan XG, Huang Y, Tang FQ, Yi H. Telomerase activity of peripheral blood lymphocytes in patients with chronic hepatitis B. Immunol Lett. 2000;73(1):7-11.
20. Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6(3):241-7.
21. Dasi F, Lledo S, Garcia-Granero E, et al. Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest. 2001;81(5):767-9.
22. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34(4):570-5.
23. Kim KA, Lee JS, Jung ES, et al. [Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development]. Korean J Gastroenterol. 2006; 48(5):321-6.
24. Fu J, Zhang W, Jin S. [Telomerase activity in liver cancer and the adjacent tissue]. Zhonghua Zhong Liu Za Zhi. 1998; 20(6):434-6.
25. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101(3):524-32.
26. Suda T, Isokawa O, Aoyagi Y, et al. Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology. 2003; 27(2):402-6.
27. Hisatomi H, Kawaoto Y, Ohmura Y, Kuwahara M, Yamauchi T, Hikiji K. Detection of telomerase activity in hepatocellular carcinoma by fluorescence-based TRAP method. International Hepatology Communications. 1996;6(1):29-35.
28. Huang GT, Lee HS, Chen CH, et al. Telomerase activity and telomere length in human hepatocellular carcinoma. Eur J Cancer. 1998; 34(12):1946-9.
29. Shimojima M, Komine F, Hisatomi H, Shimizu T, Moriyama M, Arakawa Y. Detection of telomerase activity, telomerase RNA component, and telomerase reverse transcriptase in human hepatocellular carcinoma. Hepatol Res. 2004;29(1):31-8.
30. Cavin LG, Romieu-Mourez R, Panta GR, et al. Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes. Hepatology. 2003; 38(6):1540-51.
31. He H, Xia HH, Wang JD, et al. Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma. Cancer. 2006;106(6):1243-9.
32. Jagadeesh S, Kyo S, Banerjee PP. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res. 2006;66(4):2107-15.
33. Nittis T, Guittat L, Stewart SA. Alternative lengthening of telomeres (ALT) and chromatin: is there a connection? Biochimie. 2008; 90(1):5-12.